Okairos Purchased for $324M By Glaxo

Source: PharmaManufacturing.com

May 31, 2013

Bloomberg.com

GlaxoSmithKline Plc has acquired Swiss developer Okairos AG for $324 million and was an all-cash purchase. Okairos is a developer of vaccine technologies and GlaxoSmithKline hopes to expant its range of inoculations.

Included in the deal are early stage products targeting respiratory syncytial virus, hepatitis C, malaria, tuberculosis, ebola and HIV. GlaxoSmithKline is the U.K.'s biggest drugmaker and has said there are plans to use technology from Okairos, such as genetic material delivery via virus, to produce vaccines that prevent infections and fight diseases. Read the full story.
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments